MedTrace Logo

Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With ARDS

NCT05238532 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-04-04

No results posted yet for this study

Summary

Evaluate the safety, tolerability, efficacy and pharmacodynamics\&pharmacokinetic properties of CT303 in patients with ARDS.

Conditions

  • Acute Respiratory Distress Syndrome

Interventions

GENETIC

CT303

Once a time, intravenous injection * CT303 Starting Dose : 1.0\*10\^6 cells/kg * CT303 Increasing Quantity Dose : 2.0\*10\^6 cells/kg

Sponsors & Collaborators

  • GC Cell Corporation

    lead INDUSTRY

Principal Investigators

  • Young-Jae Cho, MD, MPH, PhD · Seoul National University Bundang Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-26
Primary Completion
2023-02-22
Completion
2023-02-22

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05238532 on ClinicalTrials.gov